Caxton Associates (New York)’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-27,369
| Closed | -$1.48M | – | 481 |
|
|
2024
Q1 | $1.48M | Buy |
27,369
+1,430
| +6% | +$77.5K | 0.08% | 165 |
|
|
2023
Q4 | $1.33M | Hold |
25,939
| – | – | 0.07% | 186 |
|
|
2023
Q3 | $1.51M | Buy |
25,939
+14,204
| +121% | +$824K | 0.21% | 83 |
|
|
2023
Q2 | $750K | Buy |
11,735
+1,771
| +18% | +$113K | 0.11% | 191 |
|
|
2023
Q1 | $691K | Sell |
9,964
-15,940
| -62% | -$1.1M | 0.1% | 204 |
|
|
2022
Q4 | $1.86M | Buy |
+25,904
| New | +$1.86M | 0.12% | 37 |
|
|
2022
Q3 | – | Sell |
-8,082
| Closed | -$622K | – | 477 |
|
|
2022
Q2 | $622K | Buy |
+8,082
| New | +$622K | 0.06% | 206 |
|
|
2020
Q3 | – | Sell |
-11,019
| Closed | -$648K | – | 318 |
|
|
2020
Q2 | $648K | Buy |
+11,019
| New | +$648K | 0.06% | 84 |
|
|
2018
Q2 | – | Sell |
-4,572
| Closed | -$289K | – | 338 |
|
|
2018
Q1 | $289K | Buy |
+4,572
| New | +$289K | 0.01% | 248 |
|
|
2017
Q3 | – | Sell |
-6,600
| Closed | -$368K | – | 448 |
|
|
2017
Q2 | $368K | Buy |
+6,600
| New | +$368K | 0.01% | 363 |
|